Primary care management of the heart failure patient requiring an implanted cardioverter defibrillator.

2019 ◽  
Author(s):  
◽  
Valerie Murphy Moore

Heart failure is a chronic, progressive disease that remains on the rise partially due to improvements in preventing cardiac related mortality from other causes. Implanted cardioverter defibrillators are indicated for patients that are at high risk for sudden cardiac death from ventricular arrhythmias (primary prevention), or for those who have survived a cardiac death (secondary prevention). Guidelines suggest simple and easy to follow directions for providers to determine which patients would be eligible to be considered for a device. However, despite national guidelines, research supporting cost effectiveness, and a repeatedly demonstrated reduction in mortality with device therapy, referral and utilization of ICDs remain low, with most of the non-referral and underutilization rates identified within the primary care provider group. In addition, for those patients who do receive ICDs, advanced care planning with consideration of deactivation of the device at end-of-life is rarely completed, leaving many patients at risk of undignified and painful shocks delivered within the last hours to days of life. This integrative review seeks to explore: Primary care management of the heart failure patient requiring an implanted cardioverter defibrillator. A comprehensive search of the literature was undertaken and 15 articles were selected for inclusion This review establishes that ICDs are effective and relatively low-risk devices that have significant mortality benefits, and patients with HF should be screened routinely for eligibility for the device in order to help prevent SCD. Furthermore, patients who receive an ICD should complete an informed advance care directive which includes directions for management of the ICD at end-of-life. ICD management, while often deferred to specialists, requires a collaborative approach and consistent evaluation from the patient’s primary care provider, as it has the potential to influence all aspects of patient’s quality of life, as well as quality of end-of-life care. Recommendations for practice, education, further research, and policy have been made to support the role of primary care providers, such as Nurse Practitioners, in the management of HF patients requiring an ICD.

2007 ◽  
Vol 186 (9) ◽  
pp. 441-445 ◽  
Author(s):  
Robyn A Clark ◽  
Kerena A Eckert ◽  
Simon Stewart ◽  
Susan M Phillips ◽  
Julie J Yallop ◽  
...  

JAMA ◽  
2016 ◽  
Vol 315 (24) ◽  
pp. 2703 ◽  
Author(s):  
Konrad Schmidt ◽  
Susanne Worrack ◽  
Michael Von Korff ◽  
Dimitry Davydow ◽  
Frank Brunkhorst ◽  
...  

Author(s):  
Anna Teresińska ◽  
Olgierd Woźniak ◽  
Aleksander Maciąg ◽  
Jacek Wnuk ◽  
Jarosław Jezierski ◽  
...  

Abstract Objective Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [123I]I-metaiodobenzylguanidine (MIBG) enables assessment of the cardiac adrenergic nervous system. Tomographic imaging of the heart is expected to be superior to planar imaging. This study aimed to determine the quality and utility of MIBG SPECT in the assessment of cardiac innervation in postinfarction HF patients without DM, qualified for implantable cardioverter defibrillator (ICD) in primary prevention of sudden cardiac death. Methods Consecutive patients receiving an ICD on the basis of contemporary guidelines were prospectively included. Planar MIBG studies were followed by SPECT. The essential analysis was based on visual assessment of the quality of SPECT images (“high”, “low” or “unacceptable”). The variables used in the further analysis were late summed defect score for SPECT images and heart-to-mediastinum rate for planar images. MIBG images were assessed independently by two experienced readers. Results Fifty postinfarction nondiabetic HF subjects were enrolled. In 13 patients (26%), the assessment of SPECT studies was impossible. In addition, in 13 of 37 patients who underwent semiquantitative SPECT evaluation, the assessment was equivocal. Altogether, in 26/50 patients (52%, 95% confidence interval 38–65%), the quality of SPECT images was unacceptable or low and was limited by low MIBG cardiac uptake and by comparatively high, interfering MIBG uptake in the neighboring structures (primarily, in the lungs). Conclusions The utility of MIBG SPECT imaging, at least with conventional imaging protocols, in the qualification of postinfarction HF patients for ICD, is limited. In approximately half of the postinfarction HF patients, SPECT assessment of cardiac innervation can be impossible or equivocal, even without additional damage from diabetic cardiac neuropathy. The criteria predisposing the patient to good-quality MIBG SPECT are: high values of LVEF from the range characterizing the patients qualified to ICD (i.e., close to 35%) and left lung uptake intensity in planar images comparable to or lower than heart uptake.


Sign in / Sign up

Export Citation Format

Share Document